Lurasidone Effects on Tissue Glutamate in Schizophrenia
Completed · Phase 4
Conditions studied: Schizophrenia, Schizoaffective Disorder
In brief
24 individuals with schizophrenia or schizoaffective disorders, who are currently considered stable, will be recruited, screened for entry criteria into a blinded study with a 4-week randomization to either lurasidone, haloperidol, or perphenazine to examine glutamate-related outcomes with lurasidone as compared to haloperidol and perphenazine.
Key facts
- Study ID
- NCT02199743
- Run by
- University of Texas Southwestern Medical Center
- People needed
- 35
- Starts
- 2013-02-01
- Expected to finish
- 2016-06-01
- Last updated by the study team
- 2021-03-01
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject at least 18 years old
- Subject meets criteria diagnosis of schizophrenia or schizoaffective disorder.
- Subject is not pregnant and is not planning pregnancy within the projected duration of the study.
- Female subject who is of reproductive potential agrees to remain abstinent or use adequate and reliable contraception throughout the study
- Subject is in good physical health on the basis of medical history, physical examination, and laboratory screening.
- Eyesight corrected to 20-40 or better
- Able to read, speak, and understand English*
You may not qualify if…
- Any medications being used as mood stabilizers (i.e., anticonvulsants)
- Subject currently has a clinically significant medical condition(s) that would pose a risk to the subject if they were to participate in the study or that might confound the results of the study.
- Subject demonstrates evidence of acute/chronic hepatitis which is clinically significant
- Subject has a history of malignancy < 5 years prior
- Subject has a history of neuroleptic malignant syndrome (NMS).
- Subject has a history of alcohol or substance abuse within 3 months prior to screening or alcohol or substance dependence within 12 months prior to screening
- Subject tests positive for drugs of abuse at screening. In the event a subject tests positive for cannabis, the investigator will evaluate the subject's ability to abstain from cannabis during the study.
- Subjects diagnosed with type 1 diabetes
- Subject has a prolactin concentration > 200 ng/mL at screening
- Subject has a history or presence of abnormal ECG which is clinically significant
- Subject has a history of hypersensitivity to more than two distinct chemical classes of drug (e.g., sulfas and penicillins).
- Subjects have received depot neuroleptics within 12 weeks prior to randomization.
- Subject has a history of treatment with clozapine for refractory psychosis and/or subject has been treated with clozapine within 4 months of randomization.
- Subject does not have a stable residence for the 3 months prior to randomization.
- Subject requires treatment with any potent CYP3A4 inhibitors or inducers during the study.
- Subject has received electroconvulsive therapy (ECT) within 90 days prior to
- Subject has been randomized in a prior clinical trial of lurasidone.
- History of serious head injury with unconsciousness for >30 minutes
Where it is running
- UT Southwestern Medical Center — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.